RE: Meanwhile20 Feb 2021 20:55
It’s been a sluggish few weeks
Avacta Group Phase I Clinical Trial Approval by MHRA for AVA6000 February 18, 2021
Avacta Group SARS-CoV-2 lateral flow antigen test results show excellent performance February 16, 2021
Avacta Group announce commercial partnership with Mologi to accelerate CE marking of rapid antigen test February 8, 2021
Avacta Group secures AffyXell $7.3 Million Series A venture funding February 1, 2021
Avacta Group announce agreement with POINT Biopharma Inc. for pre|CISION™ technology January 7, 2021
Avacta Group submits application for AVA6000 Pro-doxorubixin trial December 23, 2020
Avacta Group significant progress made on SARS-CoV-2 rapid antigen test November 23, 2020
Avacta Group launch of SARS-CoV-2 BAMS research test September 30, 2020
Avacta Group a period of significant advancement September 28, 2020
Avacta Group pleased with promising evaluation of Affimer reagents in Integumen’s sensor systems September 24, 2020